227. Osler disease Clinical trials / Disease details
Clinical trials : 54 / Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-004179-11-IT (EUCTR) | 03/09/2021 | 17/08/2021 | Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telangiectasia | Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagictelangiectasia and symptomatic gastrointestinal bleeding, SAIPAN-trial: a multicentre,randomized, open-label, parallel-group, superiority trial. - SAIPAN study | Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease(in specific patients with gastrointestinal bleeding and transfusion dependency) MedDRA version: 21.0;Level: PT;Classification code 10019883;Term: Hereditary haemorrhagic telangiectasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: octreotide a azione pronta 0,1 mg Product Code: [OCTREOTIDE ACETATO] INN or Proposed INN: OCTREOTIDE ACETATO | RADBOUD UNIVERSITY MEDICAL CENTER | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 38 | Phase 3 | France;Denmark;Netherlands;Germany;United Kingdom;Italy |